Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

Guardant Health earns the No. 12 rank among its peers in the Medical-Services industry group. GeneDx Holdings WGS, Hims & Hers Health HIMS and Stevanato Group STVN are among the top 5 highly rated ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

James Van Der Beek is sharing the subtle colorectal cancer symptom he ignored before his shocking diagnosis. “There wasn’t ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

You can expect Guardant Health to continue garnering more success in the coming years. With the current trajectory, the flagship (Guardant360) is generating an extremely robust revenue increase.

Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer ...

With a stock down nearly 50% over the last 52 weeks, investors in Guardant Health (GH -2.49%) haven't had a lot to cheer about this year. The last couple of days, however, may be changing that.

Guardant Health has seen its share price soar 78% in 2019, but it's still a relatively small company with a leading position in what could become a $100 billion market. Here's why this under-the ...

Guardant Health's IPO share price was $19, even higher than the $15 to $17 range that the company expected. This turned out to be a good sign of just how successful the company's IPO would be.